HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Lasmiditan

HCID 11610526
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
439239-90-4
Standard SMILES
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
InChIKey
XEDHVZKDSYZQBF-UHFFFAOYSA-N
Molecular formula
C19H18F3N3O2
Average molar mass
377.4 g/mol
Monoisotopic mass
377.13511131

Overview

Lasmiditan is a DEA Schedule V controlled substance. Substances in the DEA Schedule V have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. It is a Depressants substance.

Names & identifiers

Preferred name
Lasmiditan
IUPAC
2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridinyl]benzamide
English name
LasMiditan
Molecular formula
C19H18F3N3O2
Molecular weight
377.36

Names & synonyms

Lasmiditan439239-90-4COL-1442,4,6-Trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl)benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamideCOL 144760I9WM792DTXSID40469435lasmiditanumRefChem:58578DTXCID002034182,4,6-trifluoro-n-(6-((1-methylpiperidin-4-yl)carbonyl)pyridin-2yl)benzamide
Show more names
LasMiditan (COL-1442,4-difluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl)benzamideCS-2381LamiditamLamiditanLasmiditant13C-Lasmiditan
MFCD18633238ReyvowLY573144lasmitidan2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridinyl]benzamide2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide2,4,6-tris(fluoranyl)-N-[6-(1-methylpiperidin-4-yl)carbonylpyridin-2-yl]benzamide

Database identifiers

Properties

Computed structural propertiesFilling in

XLogP
2.8
Topological polar surface area
62.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
7
Rotatable bonds
4
Heavy atoms
27
Formal charge
0
Complexity
530

Experimental & physicochemical properties

Drugs · 3 items

DEA Schedule V Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Unknown

Human Drugs · 3 items

Breast Feeding; Lactation; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Vasoconstrictor Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

Physicochemical properties

Melting point
255 ℃ · 255℃
Boiling point
433.3 · 433.3±45.0 °C(Predicted)
Density
1.351 · 1.351
storage temp.
-20 °C · -20°C Freezer, Under inert atmosphere
solubility
Chloroform (Slightly), DMSO (Slightly)
pka
9.91 · 9.91±0.70(Predicted)
form
Solid
color
White to Off-White

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Regulatory InformationDEA schedule V controlled substance

Toxicology

Hepatotoxicity · 1 item

In preregistration controlled trials of lasmiditan in several thousand patients, mild-to-moderate serum aminotransferase elevations arose in a small percentage of patients (1% or less) and overall rates were not different from those in placebo recipients. In the controlled trials and subsequently with general use, there have been no reports of liver injury with symptoms or jaundice attributed to lasmiditan.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H319
Precautionary statements
P264-P280-P305+P351+P338-P337+P313

Chemistry & industry

Pharmacology

ATC Code · 2 items

N - Nervous system

QN - Nervous system

Protein BindingLasmiditan exhibits a concentration-independent plasma protein binding of approximately 55-60%.
Pharmacodynamics · 1 item

Lasmiditan belongs to a new and novel class of acute anti-migraine medications that exert their effects via inhibition of neuronal firing rather than vasoconstriction of cerebral arteries. Lasmiditan appears to have a relatively quick onset of action (an important characteristic in acute migraine treatment) with some patients reporting benefit within 20 minutes. Due to its ability to cause CNS depression (e.g. drowsiness, dizziness), lasmiditan may cause significant driving impairment and patients should be advised not to participate in activities requiring mental alertness for at least 8 hours after dosing. Lasmiditan may carry some potential for abuse and should be used with caution in patients who may be at risk of drug abuse - its controlled substance scheduling is currently under review in the United States by the Drug Enforcement Administration (DEA). The safety of lasmiditan in pregnancy is unknown and is currently being monitored with a pregnancy exposure registry created by Eli Lilly and Company.

Mechanism of Action · 1 item

The acute treatment of migraine headaches has, in the past, been achieved via constriction of cerebral blood vessels, as the acute dilation of these vessels observed during migraines was thought to be the cause of the associated pain. The neurogenic hypothesis of migraine pathophysiology, an alternative to the vascular hypothesis, suggests that cerebral vasodilation is a secondary mechanism in migraine pathogenesis, and that the main contributor to migraine headache pain is the increased pathogenic firing of trigeminal nerve pathways. While the precise mechanism of action of lasmiditan is unclear, it likely supports this neurogenic hypothesis by exerting its therapeutic effects through potent and selective agonism of the 5-HT<sub>1F</sub> receptor. 5-HT<sub>1F</sub> receptors are found in both the central and peripheral nervous system (on the central and peripheral ends of trigeminal neurons) and appear to contribute to hyperpolarization of nerve terminals and inhibition of trigeminal neuronal activity. Lasmiditan's agonism at these receptors may, therefore, inhibit the firing of trigeminal nerves responsible for migraine headache pain. Lasmiditan has virtually no affinity for other 5-HT receptor subtypes or monoamine receptors (e.g. adrenergic, dopaminergic).

Related reactions

14 records
New reaction record
HRID 30219 reaction equation
HRID 30219As reactant
HRID 30225 reaction equation
HRID 30225As reactant
HRID 404239 reaction equation
HRID 404239As reactant
HRID 404245 reaction equation
HRID 404245As reactant
HRID 666419 reaction equation
HRID 666419As product
HRID 685587 reaction equation
HRID 685587As reactant
HRID 1667344 reaction equation
HRID 1667344As reactant
HRID 1667350 reaction equation
HRID 1667350As reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CAS
439239-90-4
PubChem CID
11610526
DTXSID
DTXSID40469435
ChEMBL
CHEMBL3039520
UNII
760I9WM792
Nikkaji
J2.994.454G
FDA UNII
760 I9WM792 · 760I9WM792
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
319 · H319
Precautionary statements
264 · P264-P280-P305+P351+P338-P337+P313
Biological Half-LifeThe mean elimination half-life of lasmiditan is 5.7 hours.
Metabolism/Metabolites · 1 item

The hepatic and extra-hepatic metabolism of lasmiditan is catalyzed primarily by non-CYP enzymes, with ketone reduction appearing to be the primary pathway. While the specific enzymes involved in the metabolism of lasmiditan have not been elucidated, FDA labeling states that the following enzymes are _not_ involved in its metabolism: monoamine oxidases, CYP450 reductase, xanthine oxidase, alcohol dehydrogenase, aldehyde dehydrogenase, and aldo-keto reductases. The metabolites of lasmiditan have not been characterized in published research, but two of its metabolites (M7 and M18) are considered to be pharmacologically inactive.

MeSH Pharmacological ClassificationEndogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.
Absorption, Distribution and Excretion · 3 items

Oral absorption of lasmiditan is quick, with a median tmax of 1.8 hours. An open-label study looking at absorption pharmacokinetics found the Cmax and AUC0-t of lasmiditan following oral administration to be 322.8 ± 122.0 ng/mL and 1892 ± 746.0 ng.h/mL, respectively. The oral bioavailability of lasmiditan has been reported as approximately 40%. Co-administration of lasmiditan with a high-fat meal increased its Cmax and AUC by 22% and 19%, respectively, and delayed Tmax by approximately 1 hour - these differences in absorption are relatively minor and unlikely to be clinically significant. Similarly, severe renal impairment and mild-moderate hepatic impairment were found to increase both AUC and Cmax, but not to a clinically significant extent.

Lasmiditan is eliminated primarily via metabolism, with renal excretion accounting for a small fraction of its total elimination. Of the small amount of drug found in the urine post-dose, approximately 66% is comprised of lasmiditan's S-M8 metabolite. Only 3% of an administered dose of lasmiditan was recovered unchanged in the urine, further implying a relatively extensive metabolism of this drug.

Lasmiditan has been shown to penetrate the blood-brain barrier.

Applications · 2 items

DescriptionLasmiditan (Item No. 28369) is an analytical reference standard categorized as an agonist of the serotonin (5-HT) receptor subtype 5-HT1F. Formulations containing lasmiditan have been used in the treatment of migraine headache. Lasmiditan has low abuse potential. Lasmiditan is regulated as a Schedule V compound in the United States. This product is intended for research and forensic applications.

UsesLasmiditan is used in diagnosing, treating and/or preventing periodontal disease and/or tooth loss.

Upstream & downstream products

Upstream raw materials

N-Methoxy-N,1-diMethylpiperidine-4-carboxaMide(6-aMinopyridin-2-yl)(1-Methylpiperidin-4-yl)Methanone2-Amino-6-bromopyridine2,4,6-Trifluorobenzoyl chloride4-Piperidinecarbonyl chloride, 1-methyl- (9CI)1-Methyl-piperidine-4-carboxylic acid4-Chloro-N-methylpiperidine